Conclusions Of Rituximab Treatment In

The case reports and trials clearly show that rituximab has significant activity in HCL, with a total of 18 CRs out of 60 patients (30%) treated on the four small trials. Trials with the highest CR rates (53-55%) were small and included patients without preexisting cytopenias, but it is also possible that 8-12 doses of rituximab were more effective than 4. As rituximab was associated with minimal toxicity in HCL patients, it should be strongly considered in patients who relapse from purine analog therapy. Rituximab has also shown efficacy for treating autoimmune throm-bocytopenia,46 and was reported to effectively treat this condition as a complication from pentostatin therapy.47

0 0

Post a comment